


ORDERING INFORMATION

Stent Ø (mm)	Stent Length (mm)							
	9	13	15	18	23	28	33	38
2.50	225-092-11	225-132-11	225-152-11	225-182-11	225-232-11	225-282-11	225-332-11	-
2.75	227-092-11	227-132-11	227-152-11	227-182-11	227-232-11	227-282-11	227-332-11	-
3.00	230-092-11	230-132-11	230-152-11	230-182-11	230-232-11	230-282-11	230-332-11	230-382-11
3.50	235-092-11	235-132-11	235-152-11	235-182-11	235-232-11	235-282-11	235-332-11	235-382-11
4.00	240-092-11	240-132-11	240-152-11	240-182-11	240-232-11	240-282-11	240-332-11	240-382-11

TECHNICAL SPECIFICATIONS

Stent		Delivery System	
Drug (dose)	Sirolimus (5.0 µg/mm)	Catheter type	Rapid exchange
Polymer	Abluminal bioabsorbable	Guiding catheter compatibility	5F
Biological coating	Anti-CD34 antibody	Guidewire compatibility	0.014"
Side Branch Access	4.5 mm	Coating (distal shaft / tip)	Hydrophilic coating
Radial Strength	> 25 psi	Nominal pressure (NP)	9 atm
Foreshortening	< 1%	Rated burst pressure (RBP)	16 atm
Recoil	< 5%		

* Proprietary technology



For more information please visit our website at www.OrbusNeich.com or contact us:

Corporate Headquarters

Unit 303 & 305, 3/F, Building 20E
 Hong Kong Science Park
 Shatin, N.T., Hong Kong, China
 Phone +852.2802.2288
 Fax +852.2507.3532

EMEA Regional Headquarters

Drs. W. van Royenstraat 5
 3871 AN Hoevelaken
 The Netherlands
 Phone +31.33.254.1150 Toll Free Phone 00800.0254.1150*

* Only for Belgium, Denmark, France, Germany, Ireland, Netherlands, Norway, Sweden and UK


©2021 OrbusNeich Medical Company Limited or its affiliates. All rights reserved.

Not available for sale in the USA.


G-70-0589 Rev 04

COMBO® and OrbusNeich are registered trademarks of OrbusNeich Medical Company Limited or its affiliates. All data and photos on file. Illustrations are not to be considered as engineering drawings or photos.

The Pro-Healing DES




Designed for rapid vessel healing
 and superior clinical safety



The Pro-Healing DES....

Designed for rapid vessel healing and superior clinical outcome.



9,600+ subjects enrolled with diverse patient population and complex indications

~70%

Rapid strut coverage by 1 month¹

Lumen

OCT documented vessel healing with late luminal gain from 9 to 24 m¹

P<0.001

Superior healthy tissue coverage vs. Xience²

100% ACS RCT

The ONLY COMPANY with the LARGEST PROSPECTIVE 100% ACS RCT (incl. STEMI) with approved SHORT DAPT flexibility based on non-inferiority of 3m vs. 12m³

< 1% ST

Durable low stent thrombosis rate of < 1% at 5 years in high-risk patients including ACS⁴


Short DAPT

CE approved for short DAPT flexibility in stable and ACS patients

Luminal Surface Proprietary anti-CD34 antibody coating induces functional endothelial layer

Abluminal Surface Sirolimus elution via a bioabsorbable polymer that degrades within 90 days to reduce neointimal hyperplasia

Optimal Stent Design and Mechanical Properties



¹ Lee SW, et al., Circ Cardiovasc Interv 2016;9.

² Saito S, et al., Eur Heart J 2018;39:2460-2468.

³ De Luca G, et al., EuroIntervention 2019;15:e990-e998.

⁴ Kerkmeijer LS, et al., Cardiovasc Revasc Med 2020;21:567-570.